US IPO Pipeline SEC S-1 Filings — April 08, 2026

08-04-2026

Integrated Rail & Resources Inc. (f/k/a Uinta Infrastructure Group Corp.) filed an S-1 registration statement on April 7, 2026, for an initial public offering of up to an undisclosed number of shares of common stock (par value $0.0001) on the Nasdaq Capital Market tier under the symbol IRRX, with no public market currently existing and listing approval uncertain. The filing also registers for resale 16,260,560 shares of common stock by selling stockholders, including 9,400,000 warrant shares issuable upon exercise of private warrants issued in November 2021. The company qualifies as an emerging growth company and smaller reporting company, with the resale prospectus differing in sections like use of proceeds and selling stockholders.

• ·Principal executive offices: 400 W. Morse Boulevard, Suite 220, Winter Park, FL 32789; Phone: (321) 972-1583
• ·Former company name: Uinta Infrastructure Group Corp.; Date of name change: November 7, 2024
• ·Private warrants issued pursuant to agreement dated November 11, 2021
• ·SEC file number: 333-294925; EIN: 33-1825873; State of incorporation: Delaware; SIC: 6770
• ·Underwriters granted 45-day over-allotment option for additional undisclosed shares

08-04-2026

CECO Environmental Corp has filed an S-4 registration statement as a joint proxy statement/prospectus for its proposed mergers with Thermon Group Holdings, Inc., subject to conditions including stockholder approvals, HSR Act clearance (terminated early on April 2, 2026), Nasdaq listing, and a tax opinion confirming reorganization status under Section 368(a). Key risks include potential failure to close leading to termination fees of $105.0M (CECO to Thermon) or $74.7M (Thermon to CECO), business restrictions pre-closing, market fluctuations affecting stock consideration value (fixed exchange ratios of 0.8110 or 0.6840 shares per Thermon share), proration mechanics altering elected consideration forms, and litigation risks. Thermon stockholders face uncertainty in tax consequences and trading restrictions on elected shares until closing.

• ·HSR Act waiting period terminated early by FTC effective April 2, 2026
• ·Stock exchange ratios: 0.8110 shares of CECO common stock for stock consideration; 0.6840 shares plus $10.00 cash for mixed consideration, per Thermon share
• ·Closing conditions include CECO stockholder approval of stock issuance, Thermon stockholder adoption of merger agreement, effectiveness of S-4, Nasdaq listing of new shares, and tax opinion from Sidley Austin LLP (or Gibson, Dunn & Crutcher LLP) on Section 368(a) reorganization qualification
• ·Merger agreement restricts business conduct pre-closing, including limits on acquisitions, indebtedness, capital expenditures, and dividends
• ·Thermon election shares restricted from trading between election submission and closing or revocation

08-04-2026

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company, filed an S-1 registration statement for its IPO on April 8, 2026, to list voting common stock under the Nasdaq symbol 'AVLN', with 483,842,421 shares outstanding immediately after the offering based on December 31, 2025 data post preferred stock conversion. The company reported net losses widening to $85.2 million in 2025 from $49.7 million in 2024 (71% YoY increase in loss magnitude), driven by R&D expenses rising 67% to $76.6 million and G&A up 29% to $14.7 million, though other income declined 17% to $6.1 million; cash, cash equivalents, and marketable securities stood at $138.4 million as of year-end. Net proceeds from the IPO (estimated at $ million at midpoint price) will fund clinical development of AP01 and AP02, preclinical AP03, additional R&D, and working capital.

• ·Accumulated deficit of $265.4 million as of December 31, 2025 (up from $180.2 million as of December 31, 2024).
• ·Total assets $148.9 million and working capital $129.5 million as of December 31, 2025.
• ·Underwriters' option to purchase up to additional shares within 30 days post-offering.
• ·$15.0 million in borrowings under Term Loan Facility entered February 2026.

08-04-2026

Canary PEPE ETF filed an S-1 registration statement on April 8, 2026, to launch an exchange-traded product holding PEPE, an ERC-20 meme coin on the Ethereum Network, with shares issued in baskets of 10,000 and NAV calculated daily based on PEPE pricing at 4:00 p.m. EST. The Trust expects grantor trust tax treatment but faces IRS challenge risks and will hold up to 5% in ETH for fees, while PEPE's history includes a 2023 team wallet dump of 3.8% supply causing significant price decline and a subsequent 1.6% burn. As an emerging growth company, it benefits from JOBS Act exemptions but highlights PEPE's high speculation, volatility, and lack of utility.

• ·PEPE launched April 2023 as ERC-20 token tied to Pepe the Frog meme, with no announced blockchain utility.
• ·Trust relies on Pricing Benchmark for 4:00 p.m. EST PEPE valuation; financial statements use GAAP-consistent source.
• ·Authorized Participants deliver cash for creations; redemptions yield PEPE sale proceeds, no direct PEPE handling.
• ·IRS informal guidance relied upon for grantor trust status amid risks of reclassification as partnership or corporation.

08-04-2026

Avalon GloboCare Corp. filed an S-1 registration statement on April 8, 2026, detailing its management and board as of April 1, 2026. The board now consists of four directors, including recent resignations of Dr. Jin (effective November 30, 2025), William B. Stilley III, Wilbert J. Tauzin II, and Tevi Troy (effective February 24, 2026), with Meng Li serving as Interim CEO since November 30, 2025. Three of the four directors are independent, and the board met three times in 2025 while committees held limited meetings.

• ·All directors attended at least 75% of board and committee meetings held during their service periods.
• ·Board positions of Chairman and CEO are separated.
• ·Three directors determined independent under Nasdaq and SEC rules: Steven A. Sanders, Lourdes Felix, Michael Mathews.